ClinicalTrials.gg
TerminatedNCT04346615Updated May 2, 2024Results posted

Safety and Efficacy Trial of Zavegepant* Intranasal for Hospitalized Patients With COVID-19 Requiring Supplemental Oxygen

A Phase 2/3 interventional study of Zavegepant (BHV-3500) and Placebo in COVID-19 Infection, sponsored by Pfizer. Terminated at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-02.

Sponsored by Pfizer · Phase 2/3, Interventional, and Treatment

Why this study was terminated
Lack of enrollment due to evolution of COVID-19 pandemic with reduction in patients at risk for severe disease and growing number of effective alternative therapies

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
47
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 69 studies in COVID-19 by Pfizer — 4 open to participants now, 10 under way, 3 of them phase 3. COVID-19 · Pfizer.

Enrollment
15th of 41
47 · median 20
Started
2020
with 2 others
Phase 2/3
4 of 69
none open now
Registered
1st of 69
by date

Among the 69 studies in COVID-19 by Pfizer, this one is the 15th largest by enrollment of the 41 interventional ones that give a count, is one of 3 that started in 2020, is one of 4 in phase 2/3, and was the 1st registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

4 of the 69 studies in COVID-19 by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in COVID-19 by Pfizer, or all of them as a file.
02

Study summary

The purpose of this study is to determine if a CGRP receptor antagonist may potentially blunt the severe inflammatory response at the alveolar level, delaying or reversing the path towards oxygen desaturation, Acute respiratory distress syndrome (ARDS), requirement for supplemental oxygenation, artificial ventilation or death in patients with COVID-19 on supplemental oxygen.

* BHV-3500, formerly "vazegepant", is now referred to as "zavegepant" (za ve' je pant). The World Health Organization (WHO) International Nonproprietary Names (INN) Expert Committee revised the name to "zavegepant" which was accepted by the United States Adopted Names (USAN ) Council for use in the U.S. and is pending formal adoption by the INN for international use.

03

Conditions studied

  • COVID-19 Infection

Keywords

  • COVID-19
  • COVID
  • Coronavirus
  • Biohaven
  • Intranasal
  • SARS-CoV-2
  • BHV-3500
  • Zavegepant
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must provide in accordance with requirements of the study center's institutional review board (IRB) or eithics committee prior to the initiation of any protocol-required procedures
  2. Subjects must agree to provide all requested demographic information (i.e. gender, race)
  3. Subjects must be able to read and understand English or Spanish
  4. Subjects must be over the age of 18 years
  5. Subjects must have laboratory-confirmed SARS-CoV-2 infection as determined by PCR-based commercial or public health assay
  6. Subjects must have symptoms that require hospitalization with supplemental oxygen and / or non-invasive ventilation as determined by the admitting physician. The maximum nasal cannula O2 concentration should be determined by the treating clinician and the limitations of the specific equipment
  7. Subjects must be willing and able to comply with study-related procedures/assessments

Exclusion criteria

Exclusion Criteria:

  1. Subjects in immediate need of invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO)
  2. Subjects with an \< 30 mL/min, at the Screening Visit
  3. Prisoners or subjects who are involuntarily incarcerated
  4. Subjects who are participating in any other clinical trial while participating in this clinical trial
  5. Subjects who are under the age of 18 years
  6. Subjects who are pregnant (all potential female enrollees need to have a negative pregnancy test prior to IP administration)
  7. Subjects with multi-organ failure
  8. Subjects who have received more than 48 hours of supplemental oxygen prior to randomization
  9. Subjects with prior significant pulmonary disease (e.g., severe /ILD/CHF/IPF) are excluded
  10. Subjects receiving investigational therapies as part of a formal clinical trial for the treatment of COVID-19. During the course of this study, investigational therapies that may become "standard of care" to treat COVID-19, but are not part of a clinical trial, are allowed
  11. Subjects who are on long-acting CGRP monoclonal antibodies will be excluded including Aimovig (erenumab), Emgality (galcanezumab), Ajovy (fremanezumab), and Vyepti (eptinezumab). Additionally, the investigational oral CGRP receptor antagonist, atogepant, that is taken daily will also be excluded. Oral CGRP receptor antagonists, Nurtec ODT (rimegepant) and Ubelvy (ubrogepant) that are typically used PRN infrequently will not be excluded as long the subject was not taking them on a daily basis and does not take them during the current study
  12. Subjects who are unlikely to survive for more than 48 hours from the Screening Visit
  13. Subjects with any of the following abnormal laboratory values at screening: aspartate or ALT greater than 5x or greater than 2x ULN
  14. Subjects with known active TB, history of incompletely treated TB, suspected or known extrapulmonary TB
  15. Subjects with suspected or known systemic bacterial or fungal infections. However, empiric antibiotics are permitted.
  16. Subjects who have participated in any clinical research study evaluating an IP or therapy within 3 months and less than 5 half-lives of IP prior to the screening visit
  17. Subjects with any physical examination findings and/or history of any illness that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the subject by their participation in the study
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
47 participants (actual)

Study arms

  • Experimental
    Zavegepant

    Zavegepant (BHV-3500) 10 mg intranasal (IN) dosed every 8 hours (3 times/day) (Q8h) for 14 days

    Drug: Zavegepant (BHV-3500)

  • Placebo comparator
    Placebo

    Placebo Q8h for 14 days Subjects dosed every 8 hours; 3 times/day (Q8h)

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Mean 6 Point Ordinal Severity Rating Scale (6POSRS) Score at Day 15

    The 6POSRS score was used to assess severity and ranged from 1 to 6 where: 1= Death; 2= Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO), 3= Hospitalized, on non-invasive ventilation or high-flow oxygen devices; 4= Hospitalized, requiring supplemental oxygen; 5= Hospitalized, not requiring supplemental oxygen and 6= not hospitalized. A higher score indicated a better outcome.

    Time frame: Day 15

Secondary outcomes

  1. Percentage of Participants With a 6-Point Severity Rating of 5 or 6, Who Were Alive and Off Supplemental Oxygen at Day 29

    Percentage of participants who were alive and had a 6POSRS rating of 5 (Hospitalized, not requiring supplemental oxygen) or 6 (not hospitalized) and did not use supplemental oxygen at Day 29 were reported in this outcome measure. Participants with missing 6POSRS rating at Day 29 had the last on-study 6POSRS rating before Day 29 used. Participants with \>= 1 procedure day of supplemental oxygen use before Day 29 for an ongoing procedure were considered failures, i.e., not alive or not off of oxygen at Day 29. 95% confidence interval (CI) was based on exact Clopper and Pearson method.

    Time frame: Day 29

  2. Percentage of Participants With a 6-Point Severity Rating of 2 or 3 or Required Initiation of Invasive Mechanical Ventilation, Non-Invasive Ventilation, or a High-Flow Nasal Cannula Through Day 29

    Percentage of participants who had a 6POSRS rating of 2 (Hospitalized, on invasive mechanical ventilation or ECMO) or 3 (Hospitalized, on non-invasive ventilation or high-flow oxygen devices) or \>= 1 procedure day of ventilation or high-flow nasal cannula use on study through Day 29 were reported in this outcome measure. Participants with missing 6POSRS rating at Day 29 had all available on-study 6POSRS ratings before Day 29 used. 95% CI was based on exact Clopper and Pearson method.

    Time frame: Up to Day 29

  3. Percentage of Participants Admitted Into an Intensive Care Unit (ICU) Through Day 29

    Percentage of participants admitted into an ICU on any day through Day 29 were reported in this outcome measure. 95% CI was based on exact Clopper and Pearson method

    Time frame: Up to Day 29

  4. Number of Participants With On-Treatment Deaths, Serious Adverse Events (SAEs) and Severe Adverse Events (AEs)

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. An SAE was any untoward medical occurrence that at any dose: resulted in death; was life-threatening; required prolongation of existing hospitalization; resulted in persistent or significant disability/ incapacity; resulted in congenital anomaly/birth defect; other important medical events. Severe AEs were AEs that interrupted usual activities of daily living, significantly affected clinical status, or required intensive therapeutic intervention. On-treatment was defined as the time on study drug.

    Time frame: From first dose of study treatment on Day 1 until Day 15

  5. Number of Participants With Grade 3 or 4 On-Treatment Laboratory Test Abnormalities

    The following laboratory parameters were assessed: eosinophils, hemoglobin, leukocytes, lymphocytes (high and low), neutrophils, platelets, alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium (high and low), creatine kinase, creatinine, glomerular filtration rate (GFR) estimated Modification of Diet in Renal Disease (MDRD), glucose (high and low), lactate dehydrogenase, potassium (high and low), sodium (high and low), urate, glucose (urine) and protein (urine). Laboratory abnormalities were graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5 for all parameters except glucose and uric acid. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events Corrected Version 2.1 was used for grading glucose and uric acid. Grade 3=severe and grade 4=potentially life threatening. Number of participants with grade 3 or 4 laboratory abnormalities is reported.

    Time frame: From first dose of study treatment on Day 1 until Day 15

  6. Number of Participants With Severe or Life-Threatening Bacterial, Invasive Fungal, or Opportunistic Infections Through Day 29

    Number of participants with any severe or life-threatening bacterial, invasive fungal, or opportunistic infections through Day 29 is reported in this outcome measure. Severe= interrupted usual activities of daily living, significantly affected clinical status, or required intensive therapeutic intervention. Life threatening=Participant was at immediate risk of death from the event as it occurred; i.e., it did not include a reaction that if it had occurred in a more serious form might have caused death.

    Time frame: Up to Day 29

  7. Number of Participants With Intranasal Administration Reactions Through Day 29

    An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational product and that did not necessarily have a causal relationship with this treatment. Number of participants with any adverse events associated with intranasal administration were reported in this outcome measure.

    Time frame: Up to Day 29

  8. Percentage of Participants With >= 50% Reduction in Estimated Glomerular Filtration Rate (eGFR) From Baseline

    Percentage of participants with \>=50% reduction in eGFR from Baseline during on-treatment phase were reported in this outcome measure.

    Time frame: From Baseline (Day 1) up to Day 15

07

Results

Posted May 2, 2024

Participant flow

Participant flow — Overall Study
MilestoneZavegepantPlacebo
Started2915
Completed2210
Not completed75
Withdrew: Lost to follow-up02
Withdrew: Withdrawal by subject10
Withdrew: Death51
Withdrew: Other02
Withdrew: Randomized not treated10

Outcome measures

PrimaryMean 6 Point Ordinal Severity Rating Scale (6POSRS) Score at Day 15

The 6POSRS score was used to assess severity and ranged from 1 to 6 where: 1= Death; 2= Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO), 3= Hospitalized, on non-invasive ventilation or high-flow oxygen devices; 4= Hospitalized, requiring supplemental oxygen; 5= Hospitalized, not requiring supplemental oxygen and 6= not hospitalized. A higher score indicated a better outcome.

Time frame:
Day 15
Reported as:
Mean · Units on a scale
Mean 6 Point Ordinal Severity Rating Scale (6POSRS) Score at Day 15
Units on a scaleZavegepantPlacebo
Mean 6 Point Ordinal Severity Rating Scale (6POSRS) Score at Day 155.0 ± 1.814.5 ± 1.86
SecondaryPercentage of Participants With a 6-Point Severity Rating of 5 or 6, Who Were Alive and Off Supplemental Oxygen at Day 29

Percentage of participants who were alive and had a 6POSRS rating of 5 (Hospitalized, not requiring supplemental oxygen) or 6 (not hospitalized) and did not use supplemental oxygen at Day 29 were reported in this outcome measure. Participants with missing 6POSRS rating at Day 29 had the last on-study 6POSRS rating before Day 29 used. Participants with \>= 1 procedure day of supplemental oxygen use before Day 29 for an ongoing procedure were considered failures, i.e., not alive or not off of oxygen at Day 29. 95% confidence interval (CI) was based on exact Clopper and Pearson method.

Time frame:
Day 29
Reported as:
Number · Percentage of participants
Percentage of Participants With a 6-Point Severity Rating of 5 or 6, Who Were Alive and Off Supplemental Oxygen at Day 29
Percentage of participantsZavegepantPlacebo
Percentage of Participants With a 6-Point Severity Rating of 5 or 6, Who Were Alive and Off Supplemental Oxygen at Day 2967.9 (47.7 to 84.1)60.0 (32.3 to 83.7)
SecondaryPercentage of Participants With a 6-Point Severity Rating of 2 or 3 or Required Initiation of Invasive Mechanical Ventilation, Non-Invasive Ventilation, or a High-Flow Nasal Cannula Through Day 29

Percentage of participants who had a 6POSRS rating of 2 (Hospitalized, on invasive mechanical ventilation or ECMO) or 3 (Hospitalized, on non-invasive ventilation or high-flow oxygen devices) or \>= 1 procedure day of ventilation or high-flow nasal cannula use on study through Day 29 were reported in this outcome measure. Participants with missing 6POSRS rating at Day 29 had all available on-study 6POSRS ratings before Day 29 used. 95% CI was based on exact Clopper and Pearson method.

Time frame:
Up to Day 29
Reported as:
Number · Percentage of participants
Percentage of Participants With a 6-Point Severity Rating of 2 or 3 or Required Initiation of Invasive Mechanical Ventilation, Non-Invasive Ventilation, or a High-Flow Nasal Cannula Through Day 29
Percentage of participantsZavegepantPlacebo
Percentage of Participants With a 6-Point Severity Rating of 2 or 3 or Required Initiation of Invasive Mechanical Ventilation, Non-Invasive Ventilation, or a High-Flow Nasal Cannula Through Day 2946.4 (27.5 to 66.1)60.0 (32.3 to 83.7)
SecondaryPercentage of Participants Admitted Into an Intensive Care Unit (ICU) Through Day 29

Percentage of participants admitted into an ICU on any day through Day 29 were reported in this outcome measure. 95% CI was based on exact Clopper and Pearson method

Time frame:
Up to Day 29
Reported as:
Number · Percentage of participants
Percentage of Participants Admitted Into an Intensive Care Unit (ICU) Through Day 29
Percentage of participantsZavegepantPlacebo
Percentage of Participants Admitted Into an Intensive Care Unit (ICU) Through Day 2925.0 (10.7 to 44.9)20.0 (4.3 to 48.1)
SecondaryNumber of Participants With On-Treatment Deaths, Serious Adverse Events (SAEs) and Severe Adverse Events (AEs)

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational (medicinal) product and that did not necessarily have a causal relationship with this treatment. An SAE was any untoward medical occurrence that at any dose: resulted in death; was life-threatening; required prolongation of existing hospitalization; resulted in persistent or significant disability/ incapacity; resulted in congenital anomaly/birth defect; other important medical events. Severe AEs were AEs that interrupted usual activities of daily living, significantly affected clinical status, or required intensive therapeutic intervention. On-treatment was defined as the time on study drug.

Time frame:
From first dose of study treatment on Day 1 until Day 15
Reported as:
Count of participants · Participants
Number of Participants With On-Treatment Deaths, Serious Adverse Events (SAEs) and Severe Adverse Events (AEs)
ParticipantsZavegepantPlacebo
Death11
SAEs62
Severe AEs73
SecondaryNumber of Participants With Grade 3 or 4 On-Treatment Laboratory Test Abnormalities

The following laboratory parameters were assessed: eosinophils, hemoglobin, leukocytes, lymphocytes (high and low), neutrophils, platelets, alanine aminotransferase, albumin, alkaline phosphatase, aspartate aminotransferase, bicarbonate, bilirubin, calcium (high and low), creatine kinase, creatinine, glomerular filtration rate (GFR) estimated Modification of Diet in Renal Disease (MDRD), glucose (high and low), lactate dehydrogenase, potassium (high and low), sodium (high and low), urate, glucose (urine) and protein (urine). Laboratory abnormalities were graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5 for all parameters except glucose and uric acid. Division of AIDS (DAIDS) Table for Grading the Severity of Adult and Pediatric Adverse Events Corrected Version 2.1 was used for grading glucose and uric acid. Grade 3=severe and grade 4=potentially life threatening. Number of participants with grade 3 or 4 laboratory abnormalities is reported.

Time frame:
From first dose of study treatment on Day 1 until Day 15
Reported as:
Count of participants · Participants
Number of Participants With Grade 3 or 4 On-Treatment Laboratory Test Abnormalities
ParticipantsZavegepantPlacebo
Eosinophils00
Hemoglobin20
Leukocytes00
Lymphocytes, high00
Lymphocytes, low33
Neutrophils01
Platelets00
Alanine Aminotransferase00
Albumin10
Alkaline Phosphatase00
Aspartate Aminotransferase00
Bicarbonate00
Bilirubin00
Calcium, high00
Calcium, low00
Creatine Kinase10
Creatinine11
Glomerular Filtration Rate, Estimated MDRD11
Glucose, high52
Glucose, low00
Lactate Dehydrogenase00
Potassium, high00
Potassium, low00
Sodium, high00
Sodium, low10
Urate00
Glucose, Urine00
Protein, Urine00
SecondaryNumber of Participants With Severe or Life-Threatening Bacterial, Invasive Fungal, or Opportunistic Infections Through Day 29

Number of participants with any severe or life-threatening bacterial, invasive fungal, or opportunistic infections through Day 29 is reported in this outcome measure. Severe= interrupted usual activities of daily living, significantly affected clinical status, or required intensive therapeutic intervention. Life threatening=Participant was at immediate risk of death from the event as it occurred; i.e., it did not include a reaction that if it had occurred in a more serious form might have caused death.

Time frame:
Up to Day 29
Reported as:
Count of participants · Participants
Number of Participants With Severe or Life-Threatening Bacterial, Invasive Fungal, or Opportunistic Infections Through Day 29
ParticipantsZavegepantPlacebo
Number of Participants With Severe or Life-Threatening Bacterial, Invasive Fungal, or Opportunistic Infections Through Day 2951
SecondaryNumber of Participants With Intranasal Administration Reactions Through Day 29

An AE was defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a participant or clinical investigation participant administered an investigational product and that did not necessarily have a causal relationship with this treatment. Number of participants with any adverse events associated with intranasal administration were reported in this outcome measure.

Time frame:
Up to Day 29
Reported as:
Count of participants · Participants
Number of Participants With Intranasal Administration Reactions Through Day 29
ParticipantsZavegepantPlacebo
Number of Participants With Intranasal Administration Reactions Through Day 29163
SecondaryPercentage of Participants With >= 50% Reduction in Estimated Glomerular Filtration Rate (eGFR) From Baseline

Percentage of participants with \>=50% reduction in eGFR from Baseline during on-treatment phase were reported in this outcome measure.

Time frame:
From Baseline (Day 1) up to Day 15
Reported as:
Number · Percentage of participants
Percentage of Participants With >= 50% Reduction in Estimated Glomerular Filtration Rate (eGFR) From Baseline
Percentage of participantsZavegepantPlacebo
Percentage of Participants With >= 50% Reduction in Estimated Glomerular Filtration Rate (eGFR) From Baseline7.114.3

Adverse events

Collected over On treatment: From start of study drug on Day 1 up to Day 15 and Follow up: From Day 16 to Day 60. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zavegepant (On-treatment)1/28 (3.6%)6/28 (21.4%)22/28 (78.6%)
Placebo (On-treatment)1/15 (6.7%)2/15 (13.3%)13/15 (86.7%)
Zavegepant (Follow-up)4/27 (14.8%)2/27 (7.4%)4/27 (14.8%)
Placebo (Follow-up)0/13 (0%)1/13 (7.7%)2/13 (15.4%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventZavegepant (On-treatment)Placebo (On-treatment)Zavegepant (Follow-up)Placebo (Follow-up)
Endotracheal intubationSurgical and medical procedures3/282/150/270/13
Intensive careSurgical and medical procedures3/280/150/270/13
Acute respiratory failureRespiratory, thoracic and mediastinal disorders3/280/150/270/13
Pneumonia bacterialInfections and infestations1/280/150/271/13
PneumothoraxRespiratory, thoracic and mediastinal disorders0/280/150/271/13
Respiratory failureRespiratory, thoracic and mediastinal disorders1/281/150/270/13
SepsisInfections and infestations1/281/150/270/13
Acute kidney injuryRenal and urinary disorders1/281/151/270/13
BacteraemiaInfections and infestations0/280/151/270/13
PneumoniaInfections and infestations0/280/151/270/13
Most frequent other events
Showing 10 of 50
Most frequent other events
EventZavegepant (On-treatment)Placebo (On-treatment)Zavegepant (Follow-up)Placebo (Follow-up)
DysgeusiaNervous system disorders16/281/150/270/13
HyponatraemiaMetabolism and nutrition disorders4/285/150/270/13
LeukocytosisBlood and lymphatic system disorders8/283/150/270/13
Nasal congestionRespiratory, thoracic and mediastinal disorders3/284/150/270/13
AnaemiaBlood and lymphatic system disorders4/283/151/271/13
Intensive careSurgical and medical procedures4/283/150/270/13
HyperkalaemiaMetabolism and nutrition disorders5/282/150/270/13
EpistaxisRespiratory, thoracic and mediastinal disorders3/282/150/272/13
HeadacheNervous system disorders1/282/150/270/13
HypermagnesaemiaMetabolism and nutrition disorders2/282/150/270/13

Baseline characteristics

Safety analysis set included all participants who received \>=1 dose of study drug (zavegapant or placebo)

Age, Continuous
Age, Continuous(Years)ZavegepantPlaceboTotal
Mean53.0 ± 13.4261.1 ± 12.4155.8 ± 13.49
Sex: Female, Male
Sex: Female, Male(Participants)ZavegepantPlaceboTotal
Female11516
Male171027
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)ZavegepantPlaceboTotal
Hispanic or Latino112
Not Hispanic or Latino271441
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)ZavegepantPlaceboTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American12618
White13922
More than one race000
Unknown or Not Reported202
08

Study locations

6 sites
  • Georgetown University Hospital Research Pharmacy
    Washington, District of Columbia 20007, United States
  • Georgetown University Hospital
    Washington, District of Columbia 20007, United States
  • Georgetown University Medical Center
    Washington, District of Columbia 20007, United States
  • Thomas Jefferson University Hospital
    Philadelphia, Pennsylvania 19107, United States
  • Jefferson Torresdale Hospital
    Philadelphia, Pennsylvania 19114, United States
  • Roper Hospital
    Charleston, South Carolina 29401, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2020 to primary completion in Apr 2022, 24 months.

Results were first posted in May 2024, 2 years after primary completion. A results delay was requested in Dec 2022.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2020
First posted
Apr 15, 2020
StartActual
Apr 25, 2020
Primary completionActual
Apr 29, 2022
CompletionActual
Apr 29, 2022
Results delay requested
Dec 15, 2022
Results first posted
May 2, 2024
Last update
May 2, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 2, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04346615
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 15, 2020
Start date
Apr 25, 2020
Primary completion
Apr 29, 2022
Completion
Apr 29, 2022
Results posted
May 2, 2024
Last update
May 2, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zavegepant

Start the discussion